This move is archived. Current quotes and coverage live on the stock page.
Get FRX alerts:
Fennec Pharmaceuticals Inc has seen a significant drop in its stock price, closing down 4.56% in the last trading session.
Fennec Pharmaceuticals Inc (FRX.TO) experienced a notable decline in its stock price during the last trading session, closing at CA$14.22. This 4.56% drop raises questions about investor confidence and the future outlook for the company, especially given its recent financial performance.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$599.65M
52W high
$17.64
52W low
$7.59
1W change
-15.03%
Beta
1.10
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 544.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+544.0% Upside
Current Price
C$14.53
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
83.5%
Annualized
90-Day Vol
81.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$17.37
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$15.42 | C$11.56 โ C$20.57 |
| 60 trading days | C$16.37 | C$10.89 โ C$24.60 |
| 90 trading days | C$17.37 | C$10.54 โ C$28.62 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Fennec Pharmaceuticals has shown impressive growth in recent quarters, the current stock slide may signal underlying investor concerns that need to be addressed.
Stock Down 4.56% in One Day
Fennec Pharmaceuticals Inc's market cap currently stands at CA$493.96 million, which could be affected by ongoing investor sentiment and market dynamics.
Bull case
Fennec's recent financial results show strong growth, with net product sales reaching $44.6 million in 2025, reflecting a 50% year-over-year increase. This positive trend suggests potential for recovery and long-term value.
Bear case
The recent decline in stock price might indicate investor skepticism about Fennec's ability to maintain its growth momentum, especially in a competitive pharmaceutical landscape. Without new catalysts or positive news, the stock may continue to face downward pressure.
Advertisement
Recent Performance Overview
Fennec Pharmaceuticals Inc's stock has faced a challenging trading day, closing down 4.56%. This decline comes despite the company's recent announcements of strong financial results, including a significant increase in product sales. Investors may be reacting to broader market trends or potential concerns regarding future growth.
Market Sentiment and Future Outlook
The current drop in stock price could reflect a shift in market sentiment. While Fennec has demonstrated solid growth, the lack of recent news or developments may leave investors feeling uncertain. Moving forward, the company will need to provide clear guidance and updates to reassure investors and potentially reverse this downward trend. For more insights on Fennec's performance, visit our FRX.TO stock page for detailed analysis.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
